[18F]-FDG positron imaging in clinical management of lymphoma patients

Talbot, Jean-Noël; Haı̈oun, Corinne; Rain, Jean‐Didier; Meignan, Michel; Wioland, M.; Misset, J.-L.; Grahek, D.; Kerrou, Khaldoun; Montravers, F.

doi:10.1016/s1040-8428(01)00127-5

Cited by 48 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other patient (HD), had a voluminous anterior mediastinal focal area of increased 18 FDG uptake, seen on CT as a large soft-tissue area within the mediastinum, which was attributed to residual disease. On final outcome, it was related to physiologic thymic hypermetabolism.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

¹⁸F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging

Lopci

Burnelli

Ambrosini

et al. 2008

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

This study reports on our experience with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in pediatric patients affected by Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). We studied 20 pediatric subjects (12 males, 8 females; mean age, 10 years; range, 6 months to 14 years) with malignant lymphoma (9 HD, 11 NHL) for a 4-year period of time. Overall, 45 PET scans were performed: 7 at disease presentation and 38 for evaluation of response to therapy or follow-up study. All PET results were compared with conventional imaging (CI), mainly computed tomography (CT) and/or magnetic resonance imaging (MRI), and supported by clinical follow-up and/or histologic data. In 18 of 20 patients, PET findings correctly identified the status of disease. Two (2) subjects (respectively, 1 HD and 1 NHL, both at follow-up) resulted falsely positive: 1 due to prominent thymic uptake, and the other due to nonspecific inflammation. Of 45 scans, PET findings were consistent with clinical follow-up and other CI data in 43 cases (16 true-positive and 27 true-negative results) and resulted falsely positive in the remaining 2 scans. On a lesion-by-lesion basis (overall, 153 lesions: 84 nodal and 69 extranodal), we found a concordance between CI and PET findings in 25 nodal (29.8%) and in 22 extranodal sites (32%). PET was more accurate than CI, as it identified active disease in 1 patient negative at CI and excluded relapse in 6 patients with inconclusive CI and in 2 patients with a falsely positive CI. Overall, PET sensitivity and specificity was 100% and 93% versus 94% sensitivity and 72.4% specificity for CI. This comparative study shows FDG PET to be more accurate than CI in evaluating children with lymphoma. Our data also confirms that (18)F-FDG PET may show false-positive findings.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In the management of adult lymphomas, 18 Ffluorodeoxyglucose (FDG) positron emission tomography (PET) is well established. It provides functional information, which is essential especially in the evaluation of response to treatment and of possible residual disease.…”

Section: Introductionmentioning

confidence: 99%

¹⁸F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging

Lopci

Burnelli

Ambrosini

et al. 2008

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Residual post-therapy masses are seen in up to 85% of the cases of HL and up to 40% of the cases of NHL 103104. Early interim 18 F-FDG PET/CT results (after two to four cycles) correlate well with event-free survival in HL ( Figure 6 )105–107 and high-grade NHL 108109.…”

Section: Methodsmentioning

confidence: 93%

¹⁸F-FDG PET/CT Imaging In Oncology

Almuhaideb

Παπαθανασίου

Bomanji

2011

Annals of Saudi Medicine

275

123

View full text Add to dashboard Cite

Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of managment is changed. This review provides guidance for oncologists/ radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.

show abstract

“…Review of the literature reveals only a limited number of studies that have addressed this issue. Moreover, most of these studies mixed Hodgkin and different subtypes of non-Hodgkin lymphomas and compared only PET to anatomical imaging with CT. 1,2 The clinically relevant question of how PET impacts on the staging of lymphoma and, above all, whether or not up or down staging leads to changes in therapeutic strategy has been addressed in some studies and variable results have been reported. 3,4 In a prospective study, 5 FDG-PET has been demonstrated as an efficient and non-invasive method for the primary staging of patients with untreated lymphoma.…”

Section: Primary Stagingmentioning

confidence: 99%